Barr closer to launching RLS generic

Barr Pharmaceuticals said a court backed its patent challenge of Mirapex, Boehringer Ingelheim's treatment for restless leg syndrome; Barr got FDA approval for a generic version in February. Mirapex sales came to $381 million for the 12 months ended in April, IMS Health figures show. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.